Fulcrum Therapeutics: Funding, Investors & Team (Oct 2026)
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases. The company develops a proprietary product engine that is employed to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairment and disability. It is focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases. Founded in 2016, the company is based in Cambridge, Massachusetts, United States.
Fulcrum Therapeutics has raised $375M across 3 funding rounds on record, the most recent an undisclosed round of $175M announced in Dec 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Fulcrum Therapeutics Company Profile and Key Stats
Latest funding round on record: Dec 2025.
Fulcrum Therapeutics Funding Rounds
Fulcrum Therapeutics raised $125M in a Post-IPO Equity announced in Aug 2021.
1 years later, a Post-IPO Equity of $75.0M was announced in Aug 2022.
3.3 years later, an undisclosed round of $175M was announced in Dec 2025.
Fulcrum Therapeutics Founders and Leadership Team
Contact details for the Fulcrum Therapeutics team: 1 of 3 have an email address on file.
Start 14-day free trial →Fulcrum Therapeutics Funding Compared to Other Biotechnology Startups
Fulcrum Therapeutics' latest round of $175M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Fulcrum Therapeutics in Biotechnology and Cambridge
Companies Similar to Fulcrum Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Fulcrum Therapeutics Funding FAQs
What does Fulcrum Therapeutics do?
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases. The company develops a proprietary product engine that is employed to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairment and disability. It is focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases. Founded in 2016, the company is based in Cambridge, Massachusetts, United States.
How much funding has Fulcrum Therapeutics raised?
Fulcrum Therapeutics has raised $375M across 3 rounds on record. The most recent is an undisclosed round of $175M announced in Dec 2025.
When did Fulcrum Therapeutics last raise funding?
Fulcrum Therapeutics' most recent funding round on record is an undisclosed round of $175M, announced in Dec 2025.
Who founded Fulcrum Therapeutics?
FundedIQ lists Rudolf Jaenisch (Founder) at Fulcrum Therapeutics.
Who is the CEO of Fulcrum Therapeutics?
Bryan Stuart is listed as CEO at Fulcrum Therapeutics.
Where is Fulcrum Therapeutics headquartered?
Fulcrum Therapeutics is based in Cambridge, Massachusetts, United States.
How many employees does Fulcrum Therapeutics have?
Fulcrum Therapeutics is in the 101-250 employee band.
How does Fulcrum Therapeutics' funding compare to other Biotechnology startups?
Fulcrum Therapeutics' latest round of $175M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Fulcrum Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Fulcrum Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.